Login / Signup

Impact of donor preprocurement cardiac arrest on clinical outcomes in pediatric deceased donor liver transplantation.

Joel R SchroeringTaylor J HathawayChandrashekhar A KubalBurcin EkserPlamen MihaylovRichard S Mangus
Published in: Pediatric transplantation (2020)
PPCA has historically been considered detrimental to donor quality in LT, but transplantation of grafts from this group of donors is now routine. Our study aims to evaluate the outcomes associated with use of donors with a history of PPCA in the pediatric population. This study is a single-center retrospective analysis of all pediatric LTs performed over an 18-year period. Donors and recipients were stratified by the presence and length of donor PPCA time. Preprocurement donor and post-transplant recipient laboratory values were collected to assess the degree of ischemic liver injury associated with each donor group. Cox regression analysis was used to compare survival. The records for 130 deceased pediatric LT donors and corresponding recipients were reviewed. There were 73 (56%) non-PPCA donors and 57 (44%) PPCA donors. Donors that experienced a PPCA event demonstrated a higher median, pretransplant peak alanine aminotransferase (ALT) level (P < .001). When comparing post-transplant recipient median ALT levels, donors with any PPCA had lower median peak ALT (P = .15) and day 3 ALT (P = .43) levels than the non-PPCA group. Rates of early graft loss did not differ. The PPCA group with >40 minutes of ischemia had markedly lower survival at 10 years, but this finding did not reach statistical significance. Liver grafts from donors with or without PPCA demonstrated no statistically significant differences in function or survival. A history of donor PPCA alone should not be used as an exclusionary criterion in pediatric liver transplantation.
Keyphrases
  • kidney transplantation
  • cardiac arrest
  • liver injury
  • drug induced
  • type diabetes
  • metabolic syndrome
  • cardiopulmonary resuscitation
  • young adults
  • brain injury
  • bone marrow
  • skeletal muscle
  • cell therapy
  • cerebral ischemia